Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elliot Israel

Showing results (251-260 of 322) with videos related to

Pageof 33
Sort By:
The Journal of Allergy and Clinical Immunology|March 16, 2019
Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronateJuan Carlos Cardet, Xiaofeng Jiang, Quan Lu, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2022
Caribbean Latinx with moderate-severe asthma bear greater asthma morbidity than other LatinxJuan Carlos Cardet, Kartik Shenoy, Ahmet Baydur, et al.
The Journal of Allergy and Clinical Immunology|April 25, 2024
Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthmaMonica Tang, Annabelle R Charbit, Mats W Johansson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 10, 2020
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, et al.
Lancet (London, England)|October 27, 2004
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trialElliot Israel, Vernon M Chinchilli, Jean G Ford, et al.
Science Immunology|August 8, 2017
Natural killer cell-mediated inflammation resolution is disabled in severe asthmaMelody G Duvall, Cindy Barnig, Manuela Cernadas, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2019
ReplyJuan Carlos Cardet, Xiaofeng Jiang, Quan Lu, et al.
The Journal of Allergy and Clinical Immunology|February 13, 2007
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramWendy C Moore, Eugene R Bleecker, Douglas Curran-Everett, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 1, 2025
Patient-facing digital inhalers for asthma: a systematic review and meta-analysisLeonardo Ologundudu, Daniel G Rayner, John Oppenheimer, et al.
Chest|September 16, 2019
Estimated Ventricular Size, Asthma Severity, and Exacerbations: The Severe Asthma Research Program III CohortSamuel Y Ash, Gonzalo Vegas Sanchez-Ferrero, Mark L Schiebler, et al.
Pageof 33

Showing results (251-260 of 322) with videos related to

Sort By:
Pageof 33
The Journal of Allergy and Clinical Immunology|March 16, 2019
Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronateJuan Carlos Cardet, Xiaofeng Jiang, Quan Lu, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2022
Caribbean Latinx with moderate-severe asthma bear greater asthma morbidity than other LatinxJuan Carlos Cardet, Kartik Shenoy, Ahmet Baydur, et al.
The Journal of Allergy and Clinical Immunology|April 25, 2024
Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthmaMonica Tang, Annabelle R Charbit, Mats W Johansson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 10, 2020
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, et al.
Lancet (London, England)|October 27, 2004
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trialElliot Israel, Vernon M Chinchilli, Jean G Ford, et al.
Science Immunology|August 8, 2017
Natural killer cell-mediated inflammation resolution is disabled in severe asthmaMelody G Duvall, Cindy Barnig, Manuela Cernadas, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2019
ReplyJuan Carlos Cardet, Xiaofeng Jiang, Quan Lu, et al.
The Journal of Allergy and Clinical Immunology|February 13, 2007
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramWendy C Moore, Eugene R Bleecker, Douglas Curran-Everett, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 1, 2025
Patient-facing digital inhalers for asthma: a systematic review and meta-analysisLeonardo Ologundudu, Daniel G Rayner, John Oppenheimer, et al.
Chest|September 16, 2019
Estimated Ventricular Size, Asthma Severity, and Exacerbations: The Severe Asthma Research Program III CohortSamuel Y Ash, Gonzalo Vegas Sanchez-Ferrero, Mark L Schiebler, et al.
Pageof 33